Composition for lowering blood pressure and application thereof

A technology of composition and use, applied in the field of antihypertensive composition and use, can solve problems such as insufficient attention to the effect of target organ protection

Inactive Publication Date: 2010-11-24
北京奥萨医药研究中心有限公司 +1
View PDF3 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The drugs currently used to treat hypertension mainly focus on the antihyperten...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0100] Embodiment 1 Preparation of Compound Amlodipine Losartan Folic Acid Tablets

[0101] Formula: Amlodipine Besylate 5g

[0102] Losartan 50g

[0103] Folic acid 0.4g

[0104] Lactose 50g

[0105] Microcrystalline Cellulose 50g

[0106] Starch 10g

[0107] Sodium carboxymethyl starch 30g

[0108] 10% ethanol solution of povidone

[0109] Magnesium Stearate Appropriate amount

[0110] Preparation method: crush 5g of amlodipine besylate, 50g of losartan, 0.4g of folic acid, 50g of lactose, 50g of crystal cellulose, and 10g of starch, pass through a 120-mesh sieve, mix evenly according to the method of equal addition, and use an appropriate amount of 10% povidone ethanol solution is made into a soft material, granulated, dried, and granulated, and the granules with a water content of about 3% are evenly mixed with an appropriate amount of magnesium stearate, and pressed into 1000 tablets according to a conventional method.

Embodiment 2

[0111] Example 2 Preparation of Compound Levoamlodipine Telmisartan Folic Acid Tablets

[0112] Formula: Levoamlodipine Besylate 10g

[0113] Telmisartan 20g

[0114] Folic acid 1g

[0115] Microcrystalline Cellulose 20g

[0116] Starch 80g

[0117] Sodium carboxymethyl starch 40

[0118] Proper amount of povidone aqueous solution

[0119] Magnesium Stearate Appropriate amount

[0120] The preparation method was the same as in Example 1, and each tablet was prepared to contain 10 mg of levamlodipine, 20 mg of telmisartan, and 1 mg of folic acid, with a mass ratio of 10:20:1.

Embodiment 3

[0121] Example 3 Preparation of Compound Amlodipine Irbesartan Folic Acid Tablets

[0122] Formula: Amlodipine Besylate 5g

[0123] Irbesartan 150g

[0124] Folic acid 5g

[0125] Lactose 50g

[0126] Microcrystalline Cellulose 50g

[0127] Starch 10g

[0128] Sodium carboxymethyl starch 30g

[0129] 10% ethanol solution of povidone

[0130] Magnesium Stearate Appropriate amount

[0131] The preparation method is the same as in Example 1, and each tablet is made to contain 5 mg of amlodipine besylate, 150 mg of irbesartan, and 5 mg of folic acid.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition which comprises calcium channel blockers of a medicinal dose, angiotensin II receptor antagonists of a medicinal dose, one or more of B vitamins of a medicinal dose and pharmaceutically acceptable carriers, wherein the calcium channel blockers are selected from amlodipine, felodipine, israbipine, nicardipine, nifedipine, nisoldipine, nitrendipine, lacidipine, diltiazem or verapamil; the angiotensin II receptor antagonists are selected from candesartan, telmisartan, losartan, valsartan, irbesartan, eprosartan, tasosartan or olmesartan; and the B vitamins are selected from one or more of vitamin B6, vitamin B12, folic acid and calcium leucovorin. The pharmaceutical composition of the invention can improve the curative effect of the hypotensor, enhance the target organ protecting action of the hypotensor, and reduce the morbidity of complications of angina, myocardial infarction and the like.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing a calcium channel blocker, an angiotensin II receptor antagonist and B vitamins and its application, especially a chemical drug for treating, preventing or delaying hypertension and related diseases The composition belongs to the field of pharmacy. Background technique [0002] Essential hypertension is one of the most common chronic diseases and is the main cause of serious cardiovascular diseases such as myocardial infarction, stroke, and kidney disease. The prevalence of hypertension in my country is 18.8%, and there are more than 160 million patients at present, and the prevalence of hypertension is increasing rapidly. Elevated blood pressure is an independent risk factor for stroke and coronary heart disease, and elevated blood pressure increases the risk of heart failure and kidney disease. The main purpose of treating hypertensive patients is to minimize the total risk of cardiov...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/519A61P9/12A61P9/10A61P9/04A61P13/12A61P3/04A61P3/06A61P3/10A61K31/4184A61K31/4422
Inventor 于多陈光亮徐希平
Owner 北京奥萨医药研究中心有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap